Intellia Therapeutics (NTLA) investor relations material

Executive summary

• Achieved major clinical milestones in phase III programs for lonvo-z (HAE) and nex-z (ATTR), including positive HALO/HAELO trial results and rapid resolution of clinical holds for nex-z.

• Rolling BLA submission for lonvo-z underway, with FDA acceptance anticipated in H2 2026 and potential U.S. launch in H1 2027.

• Pre-commercial readiness for lonvo-z progressing, including team hiring, disease awareness initiatives, and engagement with HAE treatment centers.

• Nex-z trials resumed globally, with strong investigator engagement, increasing screening rates, and MAGNITUDE-2 enrollment expected to complete in H2 2026.

• New genomic insights identified HLA allele linked to liver transaminase elevations in nex-z trials, with mitigation strategies implemented.

Financial highlights

• Completed $195 million equity financing in April 2026, boosting cash, cash equivalents, and marketable securities to $628.4 million as of June 30, 2026, up from $605.1 million at year-end 2025.

• Collaboration revenue was $7.7 million for Q2 2026, down from $14.2 million in the prior year quarter, mainly due to reduced Regeneron revenue.

• R&D expenses decreased to $82.6 million from $97 million year-over-year, driven by lower external costs and reduced stock-based compensation.

• G&A expenses rose to $37.8 million from $27.2 million, reflecting commercial infrastructure build-out and higher legal and stock-based compensation costs.

• Net loss for Q2 2026 was $106.6 million, compared to $101.3 million in the prior year quarter.

Outlook and guidance

• Cash runway expected to last at least into 2028, excluding any product revenues.

• Anticipates FDA acceptance of lonvo-z BLA by year-end 2026 and potential U.S. launch in first half of 2027.

• MAGNITUDE-2 enrollment for nex-z in ATTRv-PN on track for completion in H2 2026.